Core Insights - Moderna characterized 2025 as a year of execution, achieving a revenue of $1.9 billion, which was at the high end of their projected range [2] - The approval of mNEXSPIKE, their second COVID vaccine, in June contributed significantly to their market presence for the fall season [2] - The company successfully reduced costs by over $2 billion in 2025, exceeding their initial target of $1 billion [3] - As a result of these efforts, Moderna ended the year with a cash balance of $8.1 billion, which includes $600 million from other sources [3]

Core Viewpoint - Moderna Inc. has reached a settlement agreement worth $950 million with Arbutus Biopharma and Roivant's Genevant Sciences, resolving all litigation related to its COVID-19 vaccine, Spikevax, and its mRESVIA product [2][3]. Financial Implications - The settlement will involve a lump sum payment of $950 million in Q3, with potential additional payments of up to $1.3 billion depending on the outcome of a legal appeal regarding government-contractor immunity [2][3]. - If the additional payment is realized, it would represent the largest disclosed patent settlement in the pharmaceutical industry and the second largest in any industry [3]. Future Outlook - CEO Stéphane Bancel stated that resolving this litigation allows the company to focus on its near-term future, with expectations to end 2026 with $4.5 billion to $5 billion in cash and cash equivalents [3][4]. - The company anticipates returning to revenue growth in 2026 and aims for a strong balance sheet with over $5 billion in liquidity by that time, targeting breakeven in 2028 [4]. Analyst Perspectives - Following the settlement, Moderna shares have increased, as the settlement value was better than anticipated. Analysts had previously considered the potential liability to be close to $5 billion [5][6]. - Analyst Myles Minter noted that the resolution of litigation provides certainty regarding funding for multiple late-stage oncology readouts expected in 2026 [6]. Legal Context - The lawsuit alleged that Moderna's mNEXSPIKE relied on proprietary technology developed and patented by BioNTech [7]. Earnings Performance - Moderna reported a fourth-quarter loss of $2.11, which was better than the expected loss of $2.59, and lower than a loss of $2.91 a year ago. Quarterly sales reached $678 million, exceeding expectations of $626.097 million [8]. Stock Performance - The stock is currently trading 4.5% above its 20-day simple moving average (SMA) and 5.2% above its 100-day SMA, indicating short-term strength [9]. - Over the past 12 months, shares have significantly increased and are closer to their 52-week highs, reflecting a positive long-term trend. The stock carries a Hold rating with an average price target of $34.40 [10]. Recent Analyst Actions - Recent analyst ratings include Piper Sandler with an Overweight rating and a target of $69.00, Goldman Sachs with a Neutral rating and a target of $41.00, and RBC Capital with a Sector Perform rating and a target of $30.00 [11].

Summary of Moderna's Conference Call Company Overview - **Company**: Moderna - **Industry**: Biotechnology, specifically focusing on vaccines and infectious diseases Key Points Financial Performance - For the full year 2025, Moderna's product revenue reached **$1.9 billion**, at the high end of the guidance of **$1.6 billion to $2 billion** [3][4] - U.S. sales were approximately **$1.2 billion**, with vaccination rates exceeding expectations [4][5] - International sales were **$700 million**, with expectations to grow to **$1 billion** in 2026 [12][13] COVID-19 Vaccine Performance - The new COVID vaccine, **mNEXSPIKE**, achieved a **24% share** in the U.S. retail channel shortly after its approval [6] - mNEXSPIKE demonstrated **13.5% higher efficacy** compared to the previous vaccine, Spikevax, particularly among older adults [6][7] Growth Projections - Moderna anticipates **up to 10% growth** in 2026, with a balanced revenue expectation of **$1 billion** from both U.S. and international markets [8][11] - The company is planning for potential revenue adjustments based on vaccination rates and market share dynamics [12] Cost Management and Break-Even Strategy - Moderna aims for cash flow break-even by **2028**, contingent on flu vaccine outcomes and cost discipline [15] - The company has set a revenue guidance of **$3.7 billion** for 2027, with a focus on managing costs effectively [15][16] Product Pipeline and Diversification - Moderna is diversifying its portfolio beyond COVID-19 vaccines, with ongoing investments in **oncology, autoimmune diseases, and rare diseases** [19][21] - The company is exploring new modalities outside of mRNA technology, including **CAR T therapy** and **RNAi** [21][73] Regulatory and Market Opportunities - Moderna received a positive opinion for its **flu plus COVID combination vaccine** in Europe, with expectations for approval in the coming months [46][47] - The company is preparing for a significant market entry in Europe in **2027**, coinciding with the expiration of a competitor's contract [47] Norovirus and RSV Developments - Moderna is optimistic about its **norovirus vaccine**, with interim data expected in **2026** and a potential launch in **2028** [55] - The RSV vaccine is expected to see nominal growth, with a need for a revaccination schedule to drive demand [51] Oncology Pipeline - The pivotal readout for the **INT melanoma program** is anticipated in **2026**, with significant market potential for melanoma treatments [57][61] - The company is actively enrolling patients in multiple oncology trials, with a focus on rapid enrollment and event tracking [68] AI Integration - Moderna is leveraging AI to enhance productivity across various functions, with early benefits already observed in cost management [25][27] Investor Insights - Moderna's management emphasizes the strength of its team and the durability of its COVID franchise, which may be underappreciated by investors [74][75] - The company maintains a strong balance sheet, providing a solid foundation for future growth and investment opportunities [75] Conclusion Moderna is positioned for growth through its diversified product pipeline, effective cost management, and strategic market expansions. The company is optimistic about its future, particularly in the areas of oncology and infectious diseases, while also leveraging AI to improve operational efficiency.

Financial Data and Key Metrics Changes - In 2025, the company reported revenues of $1.9 billion, primarily driven by sales of the COVID vaccine Spikevax and mNEXSPIKE [4][10] - Operating expenses decreased by $2.2 billion, or 30% year-over-year, reflecting significant cost management efforts [4] - The net loss for the year was $2.8 billion, an improvement from a net loss of $3.6 billion in 2024 [14] - Cash and investments at the end of 2025 totaled $8.1 billion, down from $9.5 billion at the end of 2024 [14][15] Business Line Data and Key Metrics Changes - The company had three products on the market in 2025: Spikevax, mNEXSPIKE, and mRESVIA, with mNEXSPIKE becoming the leading product in the U.S. shortly after its launch [7] - Total revenue for the fourth quarter was $700 million, with $300 million from the U.S. and $400 million from international markets [10] - U.S. revenue for the full year was $1.2 billion, while international revenue was $700 million [10] Market Data and Key Metrics Changes - In the U.S., despite a decline in overall COVID market demand, the company maintained strong market share in the retail channel, particularly with mNEXSPIKE [11] - Internationally, the company achieved revenue at the higher end of expectations, driven by operational performance and vaccination rates [11] Company Strategy and Development Direction - The company aims for up to 10% revenue growth in 2026, primarily from international markets and local manufacturing in the U.K. and Australia [15][16] - Strategic partnerships in Latin America and Asia Pacific are expected to drive growth, alongside the anticipated launch of multiple vaccines in Europe by 2027 [20][22] - The company is focused on expanding its oncology pipeline and expects significant clinical milestones in 2026 [32] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment over the FDA's refusal to file letter regarding the flu program, highlighting challenges in the regulatory environment [5] - The company remains optimistic about its growth potential, citing strong momentum heading into 2026 with multiple levers for revenue growth [19][33] - Management emphasized the importance of cost discipline and the adoption of AI tools to improve productivity [33] Other Important Information - The company announced a five-year strategic agreement with the government of Mexico for respiratory vaccine supply [7] - A new Chief Development Officer, Dr. David Berman, was appointed to enhance the oncology pipeline [9] Q&A Session Summary Question: Implications of flu RTF on cash flow break-even guidance and INT program timing - Management noted that the flu filing is under review in Europe, Canada, and Australia, with the U.S. refile pending a Type A meeting with the FDA [37] - The INT program for adjuvant melanoma is event-driven, with data expected this year [41] Question: Thoughts on flu and COVID combination vaccine refile - The company is awaiting feedback from the FDA on what is needed to refile the mRNA-1010 program [45] - The phase III study for mRNA-1010 showed superior efficacy compared to standard vaccines [46] Question: European COVID vaccination market and flu vaccine strain selection - The company anticipates a larger market share in Europe, with mNEXSPIKE expected to be competitive [54] - Discussions on better strain matching for flu vaccines are ongoing, with strong support from international regulators [57]

Financial Data and Key Metrics Changes - In 2025, the company reported revenues of $1.9 billion, primarily driven by sales of its COVID vaccine Spikevax and mNEXSPIKE [4][10] - Operating expenses decreased by $2.2 billion, or 30% year-over-year, reflecting significant cost management efforts [4] - The net loss for the year was $2.8 billion, an improvement from a net loss of $3.6 billion in 2024 [14] - Cash and investments at year-end totaled $8.1 billion, down from $9.5 billion at the end of 2024 [14][15] Business Line Data and Key Metrics Changes - The company had three products on the market in 2025: Spikevax, mNEXSPIKE, and mRESVIA, with mNEXSPIKE quickly becoming the leading product in the U.S. [7] - Total revenue for the fourth quarter was $700 million, with $300 million from the U.S. and $400 million from international markets [10] - The U.S. revenue for the full year was $1.2 billion, while international revenue was $700 million [10] Market Data and Key Metrics Changes - In the U.S., despite a decline in overall COVID market demand, the company maintained strong market share in the retail channel, particularly with mNEXSPIKE capturing 24% of the total U.S. retail market [11][25] - Internationally, revenue performance was driven by operational efficiency and vaccination rates meeting expectations [10] Company Strategy and Development Direction - The company aims for up to 10% revenue growth in 2026, primarily from international markets and local manufacturing in the U.K. and Australia [15][16] - Strategic partnerships in Latin America and Asia Pacific are expected to drive growth, alongside the anticipated launch of multiple vaccines in 2027 [20][22] - The company is focused on expanding its oncology pipeline and expects significant clinical milestones in 2026 [32] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment over the FDA's refusal to file letter regarding the flu program, highlighting regulatory uncertainty as a challenge for innovation [5] - The company remains optimistic about its growth trajectory, citing strong momentum and multiple levers for revenue growth [19][33] Other Important Information - The company has completed enrollment in several late-stage oncology studies and anticipates data readouts in 2026 [28][32] - A new Chief Development Officer has joined the company, expected to enhance the oncology pipeline [9] Q&A Session Summary Question: Implications of flu RTF on cash flow break-even guidance and INT program timing - Management is pleased with the flu filing progress in Europe and Canada, with the U.S. refile dependent on the Type A meeting with the FDA [36] - The INT program for adjuvant melanoma is event-driven, with data expected this year [40] Question: Thoughts on flu and COVID combination vaccine re-filing - The company is awaiting feedback from the FDA on what is needed for re-filing the mRNA-1010 program [43] - The phase III study for mRNA-1010 showed superior efficacy compared to standard vaccines [45] Question: European COVID vaccination market and flu vaccine strain selection - The company anticipates a larger market than the current $700 million estimate, with mNEXSPIKE expected to capture significant share [52] - Discussions on better strain matching for flu vaccines are ongoing, with strong support from international regulators [55][57] Question: Higher-than-expected cash balance explanation - The cash balance exceeded expectations due to lower cash costs and strong working capital performance [60] Question: Details on the adjuvant phase 3 melanoma study and Norovirus confidence - The adjuvant melanoma study includes interim analyses, with the first expected this year [65] - The Norovirus vaccine is targeting older adults, with a different approach than previous studies [68]

Financial Data and Key Metrics Changes - In 2025, the company reported revenues of $1.9 billion, primarily driven by sales of its COVID vaccine Spikevax and mNEXSPIKE [5][11] - Operating expenses decreased by $2.2 billion, or 30%, compared to the previous year [5] - The net loss for the year was $2.8 billion, an improvement from a net loss of $3.6 billion in 2024 [14] - The company ended the year with $8.1 billion in cash and investments, down from $9.5 billion at the end of 2024 [14][15] Business Line Data and Key Metrics Changes - The company had three products on the market in 2025: Spikevax, mNEXSPIKE, and mRESVIA, with mNEXSPIKE quickly becoming the leading product in the U.S. [7] - For the fourth quarter, total revenue was $700 million, with $300 million from the U.S. and $400 million from international markets [11] - The U.S. revenue totaled $1.2 billion for the full year, while international revenue was $700 million [11] Market Data and Key Metrics Changes - In the U.S., despite a decline in overall COVID market demand, the company maintained strong market share in the retail channel, supported by the successful launch of mNEXSPIKE [12] - Internationally, operational performance and vaccination rates exceeded expectations, contributing to revenue growth [11] Company Strategy and Development Direction - The company aims for total revenue growth of up to 10% in 2026, primarily driven by international markets and local manufacturing agreements in the U.K. and Australia [15][16] - The company plans to launch mNEXSPIKE and its combination flu-COVID vaccine in Europe by the 2027 winter season, expanding its market share [20][21] - Strategic partnerships in Latin America and Asia Pacific are expected to drive growth, alongside the anticipated approval of its flu vaccine in multiple countries [21][27] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment over the FDA's refusal to file letter regarding the flu program, highlighting the challenges posed by regulatory uncertainty [6] - The company remains optimistic about its pipeline and expects continued clinical momentum, particularly in oncology and infectious disease programs [32][33] Other Important Information - The company has completed enrollment in several late-stage cancer studies and anticipates data readouts in 2026 [9][28] - A new Chief Development Officer, Dr. David Berman, will join the company, bringing extensive experience in clinical-stage immunotherapies [10] Q&A Session Summary Question: Implications of flu RTF on cash flow break-even guidance and INT program timing - Management noted that the flu filing is under review in Europe, Canada, and Australia, with the U.S. refile pending a Type A meeting with the FDA [36][37] - The INT program for adjuvant melanoma is event-driven, with data expected this year [42] Question: Thoughts on flu and COVID combination vaccine refile - The company is awaiting feedback from the FDA on what is needed to refile the mRNA-1010 program, with a comprehensive data set already submitted [45][47] - The phase III study for mRNA-1010 showed superior efficacy compared to standard vaccines [49][50] Question: European COVID vaccination market and flu vaccine strain selection - The company anticipates a larger market share in Europe, with mNEXSPIKE expected to be competitive [56][58] - Discussions on better strain matching for flu vaccines are ongoing, with strong support from international regulators [59][61]

Core Insights - Moderna reported Q4 revenue of $678 million, surpassing estimates of $663 million, while total sales fell 29% year-over-year due to declining COVID vaccine demand [1] - The company significantly reduced annual operating expenses by $2.2 billion, exceeding cost-reduction targets, and narrowed its quarterly loss by 26% year-over-year [1] - The FDA declined to review Moderna's flu vaccine application, delaying diversification efforts beyond COVID vaccines, which negatively impacted share prices [1] Financial Performance - Q4 revenue was $678 million, compared to a loss of $2.11 per share, better than the expected loss of $2.64 [1] - Full-year 2025 revenue was $1.94 billion, down 40% from $3.24 billion in 2024, with a reduced net loss of $2.82 billion from $3.56 billion [1] - The company held $8.1 billion in cash and investments at year-end 2025, after drawing $600 million from its credit facility [2] Cost Management - R&D spending in Q4 decreased by 31% to $775 million as the company wound down Phase 3 respiratory programs [1] - The operational efficiency achieved through cost discipline is highlighted as a significant achievement for the quarter [1] Market Dynamics - International product sales reached $381 million, surpassing U.S. sales of $264 million, indicating a strategic shift towards markets with better vaccine adoption [1] - The company secured international partnerships, including a five-year agreement with Mexico for up to 10 million COVID-19 vaccine doses [1] Regulatory Challenges - The FDA issued a Refusal-to-File letter for Moderna's flu vaccine, delaying its U.S. market entry but maintaining potential revenue from international markets [1] - Despite the setback, the company maintains that it will not impact its 2026 financial guidance [1] Future Outlook - Management projects revenue growth of up to 10% in 2026, estimating approximately $2.13 billion in sales with a balanced split between U.S. and international markets [1] - The company is advancing multiple oncology programs and rare disease therapeutics, with significant data readouts expected in 2026 [2] Valuation Considerations - Moderna's market capitalization stands at $15.67 billion, trading at 7x trailing sales despite ongoing losses [2] - Analysts have a consensus price target of $38.40, with mixed ratings reflecting the company's transition challenges [2]

Fourth Quarter 2025 Financial Results This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna's 2026 financial framework, including up to ten percent revenue growth and further cost reductions in 2026; Moderna's year-end cash balance; Moderna's multi-year revenue growth strategy; Moderna's expectations regarding durable growth supported by strategic agreements and global approvals; M ...

Core Insights - Moderna reported better-than-expected fourth quarter sales and affirmed revenue growth estimates for 2026 despite soft demand for its COVID-19 vaccine and pushback from the FDA [1] Financial Performance - The company recorded revenue of $678 million in Q4 2025 and $1.9 billion for the entire year, figures at the higher end of projections [2] - U.S. sales more than halved between Q3 and Q4 but still accounted for over 60% of full-year revenue, aided by the launch of the COVID shot mNEXSPIKE and a strong retail market [2] Future Growth Projections - Moderna reiterated a predicted growth of 10% in 2026, primarily from international markets, accounting for a decline in COVID vaccinations and no revenue from influenza or combination shots [3] Regulatory Challenges - The combination shot and standalone flu vaccine are under review in international markets but face regulatory challenges in the U.S. [4] - Moderna received a "refuse-to-file" letter for its flu vaccine, mRNA-1010, due to issues with the comparator used in its Phase 3 trial [5] - The company has requested a Type A meeting with the FDA to discuss the decision regarding mRNA-1010 [5][6] Analyst Sentiment - Analysts express caution, with RBC Capital Markets noting skepticism about the FDA reversing its decision, while Leerink Partners views the FDA letter as indicative of pressure from current leadership [7] Market Access Advocacy - Moderna's president emphasized the importance of American seniors having access to innovations similar to other markets, highlighting the need for advanced mRNA technologies in influenza vaccine development [8]

Core Insights - Moderna experienced significant growth during the early pandemic due to its rapid development of a coronavirus vaccine, with stock prices soaring over 700% and peak vaccine sales exceeding $18 billion in 2022 [1][2] - As demand for coronavirus vaccines declined, the company shifted its focus towards cost-cutting and developing a seasonal vaccine portfolio, including opportunities in oncology and rare disease therapeutics [2][9] - Recent setbacks include the U.S. FDA's decision not to review Moderna's flu vaccine application, leading to a more than 3% drop in stock price [3][4] Company Developments - Moderna's mRNA technology has been pivotal in its success, allowing the company to produce two coronavirus vaccines, Spikevax and mNEXSPIKE, both adapted for the 2025-2026 season, along with a respiratory syncytial virus (RSV) vaccine [7][8] - The company aims to launch its flu vaccine, mRNA-1010, in the global market for the 2027-2028 flu season, which is a critical component of its growth strategy [8] - Despite a recent failure of its cytomegalovirus (CMV) vaccine candidate in a phase 3 trial, Moderna continues to advance its oncology candidates and early-stage programs for rare diseases, planning to reinvest revenue from seasonal vaccines into these initiatives [9]